TY - JOUR
T1 - Cav1.4 congenital stationary night blindness is associated with an increased rate of proteasomal degradation
AU - Sadeh, Tal T
AU - Baines, Richard A
AU - Black, Graeme C
AU - Manson, Forbes
N1 - Copyright © 2023 Sadeh, Baines, Black and Manson.
PY - 2023/5/3
Y1 - 2023/5/3
N2 - Pathogenic, generally loss-of-function, variants in CACNA1F, encoding the Cav1.4α1 calcium channel, underlie congenital stationary night blindness type 2 (CSNB2), a rare inherited retinal disorder associated with visual disability. To establish the underlying pathomechanism, we investigated 10 clinically derived CACNA1F missense variants located across pore-forming domains, connecting loops, and the carboxy-tail domain of the Cav1.4α subunit. Homology modeling showed that all variants cause steric clashes; informatics analysis correctly predicted pathogenicity for 7/10 variants. In vitro analyses demonstrated that all variants cause a decrease in current, global expression, and protein stability and act through a loss-of-function mechanism and suggested that the mutant Cav1.4α proteins were degraded by the proteasome. We showed that the reduced current for these variants could be significantly increased through treatment with clinical proteasome inhibitors. In addition to facilitating clinical interpretation, these studies suggest that proteasomal inhibition represents an avenue of potential therapeutic intervention for CSNB2.
AB - Pathogenic, generally loss-of-function, variants in CACNA1F, encoding the Cav1.4α1 calcium channel, underlie congenital stationary night blindness type 2 (CSNB2), a rare inherited retinal disorder associated with visual disability. To establish the underlying pathomechanism, we investigated 10 clinically derived CACNA1F missense variants located across pore-forming domains, connecting loops, and the carboxy-tail domain of the Cav1.4α subunit. Homology modeling showed that all variants cause steric clashes; informatics analysis correctly predicted pathogenicity for 7/10 variants. In vitro analyses demonstrated that all variants cause a decrease in current, global expression, and protein stability and act through a loss-of-function mechanism and suggested that the mutant Cav1.4α proteins were degraded by the proteasome. We showed that the reduced current for these variants could be significantly increased through treatment with clinical proteasome inhibitors. In addition to facilitating clinical interpretation, these studies suggest that proteasomal inhibition represents an avenue of potential therapeutic intervention for CSNB2.
KW - CACNA1
KW - Ca 1.4
KW - bortezomib
KW - proteasome inhibitor
KW - variant pathogenicity
KW - voltage-gated calcium channel
UR - http://www.scopus.com/inward/record.url?scp=85159903645&partnerID=8YFLogxK
U2 - 10.3389/fcell.2023.1161548
DO - 10.3389/fcell.2023.1161548
M3 - Article
C2 - 37206923
SN - 2296-634X
VL - 11
JO - Frontiers in cell and developmental biology
JF - Frontiers in cell and developmental biology
M1 - 1161548
ER -